ARROWHEAD PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.57% for the 12-month period ending 2023-09-30, per its 10-K filed 2025-11-25.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2025-11-25
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-12-31 was 0.60%, a 66.67% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-12-31 was 1.80%, a 41.94% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-12-31 was 3.10%, a 39.64% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-12-31 was 2.22%, a 54.17% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.57%.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.10%, a 38.89% decline from fiscal 2020.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 1.80%, a 41.94% decline from fiscal 2019.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 3.10%, a 3.68% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-09-30 | 4.57% 10-K · filed 2025-11-25 | |||||||
| 2021-09-30 | 1.10% 10-K · filed 2023-11-29 | |||||||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-04 | |||||||
| 2021-03-31 | 0.60% 10-Q · filed 2022-05-10 | |||||||
| 2020-12-31 | 0.60% 10-Q · filed 2022-02-02 | |||||||
| 2020-09-30 | 1.80% 10-K · filed 2022-11-28 | |||||||
| 2020-06-30 | 1.80% 10-Q · filed 2021-08-05 | |||||||
| 2020-03-31 | 1.80% 10-Q · filed 2021-05-04 | |||||||
| 2019-12-31 | 1.80% 10-Q · filed 2021-02-04 | |||||||
| 2019-09-30 | 3.10% 10-K · filed 2021-11-22 | 3.11% 10-K · filed 2019-11-25 | ||||||
| 2019-06-30 | 3.10% 10-Q · filed 2020-08-05 | |||||||
| 2019-03-31 | 3.10% 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | 3.10% 10-Q · filed 2020-02-05 | 3.11% 10-Q · filed 2019-02-07 | ||||||
| 2018-09-30 | 2.99% 10-K · filed 2020-11-23 | |||||||
| 2018-06-30 | 2.80% 10-Q · filed 2019-08-05 | |||||||
| 2018-03-31 | 2.70% 10-Q · filed 2019-05-08 | |||||||
| 2017-12-31 | 2.22% 10-Q · filed 2019-02-07 | |||||||
| 2017-09-30 | 2.31% 10-K · filed 2019-11-25 | |||||||
| 2017-06-30 | 2.30% 10-Q · filed 2018-08-07 | 2.31% 10-Q · filed 2017-08-03 | ||||||
| 2017-03-31 | 2.10% 10-Q · filed 2018-05-08 | 2.06% 10-Q · filed 2017-05-03 | ||||||
| 2016-12-31 | 1.44% 10-Q · filed 2018-02-09 | |||||||
| 2016-09-30 | 1.89% 10-K · filed 2018-12-11 | |||||||
| 2016-06-30 | 1.89% 10-Q · filed 2017-08-03 | |||||||
| 2016-03-31 | 1.89% 10-Q · filed 2017-05-03 | |||||||
| 2015-12-31 | 1.81% 10-Q · filed 2017-02-06 | |||||||
| 2015-09-30 | 1.89% 10-K · filed 2017-12-12 | |||||||
| 2015-06-30 | 1.88% 10-Q · filed 2016-08-09 | |||||||
| 2015-03-31 | 1.85% 10-Q · filed 2016-05-10 | |||||||
| 2014-12-31 | 1.85% 10-Q · filed 2016-02-09 | |||||||
| 2014-09-30 | 2.40% 10-K · filed 2016-12-14 | |||||||
| 2014-06-30 | 2.50% 10-Q · filed 2015-08-04 | |||||||
| 2014-03-31 | 2.26% 10-Q · filed 2015-05-11 | |||||||
| 2013-09-30 | 2.30% 10-K · filed 2015-12-14 | |||||||
| 2013-06-30 | 1.30% 10-Q · filed 2014-08-12 | |||||||
| 2013-03-31 | 1.00% 10-Q · filed 2014-05-06 | |||||||
| 2012-12-31 | 1.00% 10-Q · filed 2014-02-04 | |||||||
| 2012-09-30 | 1.70% 10-K · filed 2014-11-25 | |||||||
| 2012-06-30 | 1.70% 10-Q · filed 2012-08-13 | |||||||
| 2011-09-30 | 2.90% 10-K · filed 2012-12-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |